Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology

Treatment Options: From Skin-Directed to Systemic Therapy

At a Glance

Treatment for primary cutaneous lymphoma (PCL) often uses a stepwise approach, prioritizing skin-directed therapies like topical gels or phototherapy for early stages. Systemic therapies, such as targeted biologics, are reserved for widespread or aggressive disease to minimize unwanted toxicity.

When it comes to treating primary cutaneous lymphoma (PCL), more is not always better. Because many forms of skin lymphoma are slow-growing (indolent), the goal of treatment is often to manage the disease like a chronic condition—clearing the skin while minimizing side effects and preserving your quality of life [1][2].

The Stepwise Approach: Skin-Directed vs. Systemic

Treatment is generally divided into two categories: skin-directed therapies (SDT), which treat only the skin, and systemic therapies, which work throughout the entire body [3].

1. Skin-Directed Therapies (For Early-Stage & Indolent Types)

For early-stage Mycosis Fungoides (patches/plaques) or indolent B-cell lymphomas (PCMZL and PCFCL), guidelines prioritize treating the skin directly [3][4].

  • Topical Steroids: Often the first line of defense to reduce inflammation and itching [5].
  • Chlormethine (Mechlorethamine) Gel: A form of “topical chemotherapy” applied directly to the skin. It is effective at killing malignant T-cells without the side effects of traditional IV chemo [6][7]. Note that this medication frequently causes localized skin irritation (contact dermatitis) [8]; this is a known side effect that your care team can help you manage, and not necessarily a sign that the disease is worsening.
  • Phototherapy: Uses specific wavelengths of light (UVB or PUVA) to treat the skin. This often requires visits to a clinic 2–3 times a week [9][10].
  • Total Skin Electron Beam Therapy (TSEBT): A specialized form of radiation that treats the entire skin surface at once. Because the electron beams only penetrate the superficial layers of the skin, it is a skin-directed therapy used for widespread disease to provide rapid relief without damaging internal organs [11][12].
  • Localized Radiation: Very effective for treating individual “indolent” B-cell nodules or resistant MF plaques [13][4].

2. Systemic Therapies (For Advanced or Aggressive Types)

If the disease is widespread, involves the blood (like Sézary Syndrome), or is an aggressive subtype (like Leg Type B-cell lymphoma), systemic medications are needed [14][15].

  • Targeted Biologics: Modern “smart” drugs like mogamulizumab (which targets the CCR4 protein) or brentuximab vedotin (which targets CD30) can find and kill lymphoma cells throughout the body [16][17].
  • Retinoids & Interferon: Pill or injectable medications that help the immune system recognize and fight the cancer [18][19].

The Danger of Overtreatment

One of the most important reasons to see a specialist is to avoid overtreatment. Doctors who are not familiar with PCL may mistakenly treat early-stage Mycosis Fungoides with aggressive, multi-agent “traditional” chemotherapy [20].

Research shows that for indolent PCL, aggressive chemotherapy often does not lead to longer remissions and can cause significant, unnecessary toxicity [20][1]. In many cases, “gentler” skin-directed treatments are just as effective at managing the disease for years [8].

When is a Transplant Considered?

For a small number of patients with very advanced or resistant disease, an allogeneic hematopoietic stem cell transplant may be discussed [21]. This is currently the only potentially curative option for PCL, but it is a major procedure with significant risks, usually reserved for when other treatments have failed [22][23].

Treatment Decision Guide

  • Early-Stage MF / Indolent B-Cell: Focus on Skin-Directed Therapies. The goal is clearance with minimal toxicity [1].
  • Widespread MF / Sézary Syndrome: Transition to Systemic Therapies (Biologics/Targeted drugs) or TSEBT [14].
  • Aggressive B-Cell (Leg Type): Requires Immediate Systemic Therapy (often traditional chemotherapy combinations) due to its faster growth [24].

Return to Home

Common questions in this guide

Why is my doctor recommending skin-directed therapy instead of traditional chemotherapy?
Many forms of primary cutaneous lymphoma are slow-growing. Treating the skin directly manages the disease effectively while minimizing the severe side effects associated with traditional systemic chemotherapy. Aggressive systemic treatments are generally reserved for more advanced stages.
What is chlormethine gel and how does it work?
Chlormethine gel is a type of topical chemotherapy applied directly to the skin. It targets and kills malignant T-cells locally without causing the widespread side effects of intravenous chemotherapy, though it can cause some local skin irritation.
When are systemic therapies used for primary cutaneous lymphoma?
Systemic therapies, such as targeted biologics or retinoids, are typically used if the lymphoma is widespread, involves the blood (like Sézary Syndrome), or is an aggressive subtype. These medications travel throughout the entire body to fight the cancer cells.
What is Total Skin Electron Beam Therapy (TSEBT)?
Total Skin Electron Beam Therapy (TSEBT) is a specialized form of radiation that treats the entire skin surface at once. Because the electron beams only penetrate the superficial layers of the skin, it provides rapid relief for widespread disease without damaging internal organs.
Will I need a stem cell transplant for primary cutaneous lymphoma?
A stem cell transplant is usually only considered for a small number of patients with very advanced or treatment-resistant disease. While it is the only potentially curative option, it is a major procedure with significant risks and is reserved for when other standard therapies have failed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my subtype and stage, are we starting with skin-directed therapies first?
  2. 2.If my disease is early-stage or indolent, why is systemic chemotherapy not recommended right now?
  3. 3.Am I a candidate for targeted therapies like brentuximab vedotin or mogamulizumab if my current treatment stops working?
  4. 4.What are the long-term side effects of phototherapy or chlormethine gel that I should watch for?
  5. 5.At what point would we consider Total Skin Electron Beam Therapy (TSEBT) for my condition?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Management Strategies for Mycosis Fungoides in India.

    Raychaudhury T

    Indian journal of dermatology 2017; (62(2)):137-141 doi:10.4103/ijd.IJD_71_17.

    PMID: 28400632
  2. 2

    Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.

    Bhat TS, Herbosa CM, Rosenberg AR, et al.

    The British journal of dermatology 2021; (184(2)):310-318 doi:10.1111/bjd.19298.

    PMID: 32510571
  3. 3

    Skin Directed Therapy in Cutaneous T-Cell Lymphoma.

    Tarabadkar ES, Shinohara MM

    Frontiers in oncology 2019; (9()):260 doi:10.3389/fonc.2019.00260.

    PMID: 31032224
  4. 4

    [Primary cutaneous B-cell lymphomas-an overview of established and novel aspects].

    Hansen-Abeck I, Menz A, Schneider SW, Booken N

    Dermatologie (Heidelberg, Germany) 2025; (76(11)):735-748 doi:10.1007/s00105-025-05605-x.

    PMID: 41128869
  5. 5

    Skin-Directed Therapies in Mycosis Fungoides: An Update.

    Tota M, Łyko M, Misiąg P, et al.

    Dermatology and therapy 2025; (15(10)):2765-2801 doi:10.1007/s13555-025-01511-1.

    PMID: 40810772
  6. 6

    Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians.

    Geskin L, Querfeld C, Hodak E, et al.

    Dermatology and therapy 2025; (15(1)):61-73 doi:10.1007/s13555-024-01305-x.

    PMID: 39602063
  7. 7

    Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice.

    Papadavid E, Koumourtzis M, Nikolaou V, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(10)):1751-1757 doi:10.1111/jdv.18183.

    PMID: 35470483
  8. 8

    Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.

    Giuliano C, Frizzarin S, Alonzi A, et al.

    Dermatology and therapy 2022; (12(11)):2517-2529 doi:10.1007/s13555-022-00813-y.

    PMID: 36229764
  9. 9

    Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study.

    Rattanakaemakorn P, Ploydaeng M, Udompanich S, et al.

    Indian journal of dermatology, venereology and leprology 2021; (87(5)):645-650.

    PMID: 33871205
  10. 10

    Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.

    Phan K, Ramachandran V, Fassihi H, Sebaratnam DF

    JAMA dermatology 2019; (155(3)):335-341 doi:10.1001/jamadermatol.2018.5204.

    PMID: 30698622
  11. 11

    Total skin electron beam therapy.

    Specht L

    Frontiers in oncology 2025; (15()):1498855 doi:10.3389/fonc.2025.1498855.

    PMID: 40236646
  12. 12

    Prospective observational trial of low-dose skin electron beam therapy in mycosis fungoides using a rotational technique.

    Newman NB, Patel CG, Ding GX, et al.

    Journal of the American Academy of Dermatology 2021; (85(1)):121-127 doi:10.1016/j.jaad.2020.12.023.

    PMID: 33333150
  13. 13

    Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report.

    Biba U, Poppens MJ, Collier EK, Cheng K

    SAGE open medical case reports 2024; (12()):2050313X241274837 doi:10.1177/2050313X241274837.

    PMID: 39399579
  14. 14

    Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.

    Miyashiro D, Sanches JA

    Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.

    PMID: 37124514
  15. 15

    Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.

    Al Dhafiri M, Sicre de Fontbrune F, Marinho E, et al.

    Clinical case reports 2019; (7(5)):964-967 doi:10.1002/ccr3.2137.

    PMID: 31110725
  16. 16

    Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

    Kim YH, Bagot M, Pinter-Brown L, et al.

    The Lancet. Oncology 2018; (19(9)):1192-1204 doi:10.1016/S1470-2045(18)30379-6.

    PMID: 30100375
  17. 17

    Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

    Horwitz SM, Scarisbrick JJ, Dummer R, et al.

    Blood advances 2021; (5(23)):5098-5106 doi:10.1182/bloodadvances.2021004710.

    PMID: 34507350
  18. 18

    The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.

    Weiner DM, Durgin JS, Wysocka M, Rook AH

    Journal of the American Academy of Dermatology 2021; (84(3)):597-604 doi:10.1016/j.jaad.2020.12.026.

    PMID: 33352268
  19. 19

    Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.

    Sanches JA, Cury-Martins J, Abreu RM, et al.

    Anais brasileiros de dermatologia 2021; (96(4)):458-471 doi:10.1016/j.abd.2020.12.007.

    PMID: 34053802
  20. 20

    Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma.

    Wang B, Li K, Wang H, et al.

    Experimental dermatology 2020; (29(10)):987-992 doi:10.1111/exd.14133.

    PMID: 32573814
  21. 21

    Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.

    Martinez XU, Di Raimondo C, Abdulla FR, et al.

    Best practice & research. Clinical haematology 2019; (32(3)):239-252 doi:10.1016/j.beha.2019.06.004.

    PMID: 31585624
  22. 22

    Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes?

    Ritchie S, Qureshi I, Molloy K, et al.

    The British journal of dermatology 2020; (182(3)):807-809 doi:10.1111/bjd.18541.

    PMID: 31536644
  23. 23

    Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.

    Bejarano L, Grau-Pérez M, Paíno-Román M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(1)):99-108 doi:10.1111/jdv.20638.

    PMID: 40065681
  24. 24

    A case of a primary cutaneous diffuse large B-cell lymphoma, leg type.

    Marasca C, Fabbrocini G, Cinelli E, et al.

    International wound journal 2020; (17(2)):514-515 doi:10.1111/iwj.13298.

    PMID: 31884690

This page provides educational information about primary cutaneous lymphoma treatment options. It is not intended to replace professional medical advice. Always consult your oncology team to determine the safest and most effective treatment plan for your specific diagnosis.

Get notified when new evidence is published on Primary cutaneous lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.